skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Vorinostat (Code C1796)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Vorinostat

Definition: A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.

NCI-GLOSS Definition: A drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Vorinostat is a type of histone deacetylase inhibitor.

Display Name: Vorinostat

Label: Vorinostat

NCI Thesaurus Code: C1796 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0672708  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Suberanilohydroxamic Acid
suberoylanilide hydroxamic acid
Suberoylanilide Hydroxamic Acid

External Source Codes: 
CAS Registry Number 149647-78-9 (see NLM ChemIDplus info)
NSC Code 701852 (see NCI DTP info)
PDQ Closed Trial Search ID 37944
PDQ Open Trial Search ID 37944 (check for NCI PDQ open clinical trial info)
UMLS CUI C0672708

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Cutaneous T-cell Lymphoma
Chemical_Formula C14H20N2O3
code C1796
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Suberoylanilide_Hydroxamic_Acid
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom